Wood et al. [23] reported that the results of CD34+ stem cell collection using intermediate-dose etoposide (375 mg/m2 for two days) plus G-CSF mobilization in 152 patients with MM, which showed that 150 (98.7%) patients could achieve optimal collection (CD34+ cells of 5 × 106/kg or greater for one to two days), but the toxicities of neutropenia (78.9%) and neutropenic fever (9.0%) were of concern to be overcome. This evidence concerns the gene CSF3 and Miyoshi myopathy.